- Home
- REVB vs NLSP Comparison
REVB vs NLSP Comparison
Compare REVB & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- NLSP
- Stock Information
- Founded
- REVB 2020
- NLSP 2015
- Country
- REVB United States
- NLSP Switzerland
- Employees
- REVB N/A
- NLSP N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- NLSP Health Care
- Exchange
- REVB Nasdaq
- NLSP Nasdaq
- Market Cap
- REVB 5.4M
- NLSP 6.2M
- IPO Year
- REVB N/A
- NLSP 2021
- Fundamental
- Price
- REVB $0.40
- NLSP $1.91
- Analyst Decision
- REVB
- NLSP
- Analyst Count
- REVB 0
- NLSP 0
- Target Price
- REVB N/A
- NLSP N/A
- AVG Volume (30 Days)
- REVB 6.8M
- NLSP 2.2M
- Earning Date
- REVB 11-08-2024
- NLSP 10-18-2024
- Dividend Yield
- REVB N/A
- NLSP N/A
- EPS Growth
- REVB N/A
- NLSP N/A
- EPS
- REVB N/A
- NLSP N/A
- Revenue
- REVB N/A
- NLSP N/A
- Revenue This Year
- REVB N/A
- NLSP N/A
- Revenue Next Year
- REVB N/A
- NLSP N/A
- P/E Ratio
- REVB N/A
- NLSP N/A
- Revenue Growth
- REVB N/A
- NLSP N/A
- 52 Week Low
- REVB $0.28
- NLSP $1.73
- 52 Week High
- REVB $25.26
- NLSP $20.80
- Technical
- Relative Strength Index (RSI)
- REVB 39.87
- NLSP 41.47
- Support Level
- REVB $0.39
- NLSP $1.87
- Resistance Level
- REVB $0.53
- NLSP $2.08
- Average True Range (ATR)
- REVB 0.13
- NLSP 0.27
- MACD
- REVB 0.00
- NLSP 0.03
- Stochastic Oscillator
- REVB 7.54
- NLSP 8.77
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.